Sasaki S, Tsuji T, Asakura Y, Fukushima J, Okuda K
Department of Bacteriology, Yokohama City University School of Medicine, Japan.
Anticancer Res. 1998 Sep-Oct;18(5D):3907-15.
DNA vaccination is a new way to generate antigen specific immune responses by inoculating plasmid DNA encoding microbial genes. We believe that the use of immunologic adjuvants together with DNA vaccines is a promising way to enhance and optimize DNA-derived immunity. Various chemical and genetic adjuvants have been explored in our recent study. Data from these studies suggests that adjuvants exert their immunomodulatory properties through several mechanisms such as lymphoid cells recruitment, cytokine induction, and the facilitation of DNA entry into cells. Furthermore, each adjuvant has unique immunomodulatory effects on cell-mediated and humoral immune responses induced by DNA vaccination to human immunodeficiency virus type 1. To optimize the desirable immune response, the choice of adjuvant and decision of immunization route are important considerations. A similar approach may be useful potentiating anticancer immunotherapy as well.
DNA疫苗接种是通过接种编码微生物基因的质粒DNA来产生抗原特异性免疫反应的一种新方法。我们认为,将免疫佐剂与DNA疫苗联合使用是增强和优化DNA衍生免疫的一种有前景的方法。在我们最近的研究中探索了各种化学和基因佐剂。这些研究的数据表明,佐剂通过多种机制发挥其免疫调节特性,如淋巴细胞募集、细胞因子诱导以及促进DNA进入细胞。此外,每种佐剂对DNA疫苗接种诱导的针对1型人类免疫缺陷病毒的细胞介导和体液免疫反应都有独特的免疫调节作用。为了优化理想的免疫反应,佐剂的选择和免疫途径的决定是重要的考虑因素。类似的方法可能对增强抗癌免疫治疗也有用。